ISIS Partnership
One of Antisense Therapeutics' fundamental strategies is acquiring access to state of the art antisense technology, in both know-how and intellectual property, to accelerate drug discovery and development.
ISIS and the ATL/ISIS Partnership
As a leader in the field, the directors believe that Isis Pharmaceuticals, Inc. is the ideal technology partner for Antisense Therapeutics.
Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis’ mission is to develop products from its RNA-based technologies, such as antisense.
A key milestone for antisense therapeutics was the 1998 US FDA approval of Isis’ first antisense drug Vitravene®. Vitravene® caters to the niche market of eye infections caused by HIV-induced cytomegalovirus.
California-based Isis is the leader in all aspects of antisense technology advancement, including mechanism research, the development of new chemistries, novel formulations and innovative drugs. The company currently has 23 products in development.
With approximately 1,600 issued patents worldwide, Isis is the owner of one of the largest antisense and RNA patent estates in the pharmaceutical industry. The Company holds key patents covering antisense mechanisms, biology, chemistry, inhibitors of gene expression and manufacturing of antisense drugs.
Isis has alliances with a number of global pharmaceutical companies, including Genzyme, Ortho-McNeil Janssen, Bristol-Myers Squibb & Eli Lily & Co.
For more information on Isis Pharmaceuticals, please visit their website at www.isispharm.com
(Vitravene is a registered trademark of Novartis AG)
ATL/ISIS Collaboration
A fundamental element of the Antisense Therapeutics strategy is its access to leading antisense technology derived from its strategic partnership with Isis. Isis has successfully commercialized the world’s first antisense drug and has 23 drugs in development (either alone or in partnership with other pharmaceutical companies). As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. Isis has several partnerships with major pharmaceutical companies, including drug development collaborations with Glaxo Smith-Kline, Genzyme, Ely Lilly & Co, and Bristol-Myers Squibb
The collaboration with Isis provides Antisense Therapeutics with access to Isis’ antisense intellectual property, development expertise and drug manufacturing capabilities to allow the Company to develop and commercialise its pipeline of antisense drugs.
